Bulletin
Investor Alert

London Markets Open in:

AbbVie Inc.

NYS: ABBV

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 18, 2020, 7:58 p.m.

/zigman2/quotes/202428675/composite

$

90.01

Change

-0.10 -0.11%

Volume

Volume 674,808

Quotes are delayed by 20 min

/zigman2/quotes/202428675/composite

Previous close

$ 89.63

$ 90.11

Change

+0.48 +0.54%

Day low

Day high

$88.86

$90.50

Open

52 week low

52 week high

$62.55

$101.28

Open

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, inc...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Valuation

P/E Current

17.05

P/E Ratio (with extraordinary items)

21.50

P/E Ratio (without extraordinary items)

16.76

Price to Sales Ratio

3.95

Price to Cash Flow Ratio

9.86

Enterprise Value to EBITDA

9.93

Enterprise Value to Sales

4.77

Total Debt to Enterprise Value

0.42

Efficiency

Revenue/Employee

1,108,867.00

Income Per Employee

261,400.00

Receivables Turnover

5.89

Total Asset Turnover

0.45

Liquidity

Current Ratio

3.18

Quick Ratio

3.06

Cash Ratio

2.56

Profitability

Gross Margin

77.14

Operating Margin

41.83

Pretax Margin

25.33

Net Margin

23.57

Return on Assets

10.56

Return on Total Capital

30.66

Return on Invested Capital

19.22

Capital Structure

Total Debt to Total Capital

113.87

Total Debt to Total Assets

75.28

Long-Term Debt to Total Capital

107.32

Officers and Executives

Name Age Officer Since Title
Mr. Richard A. Gonzalez 65 2013 Chairman & Chief Executive Officer
Dr. Michael E. Severino 53 2014 Vice Chairman & President
Dr. Azita Saleki-Gerhardt 55 2013 Executive Vice President-Operations
Mr. Robert A. Michael 48 2012 Chief Financial Officer & Senior Vice President
Dr. Thomas J. Hudson 57 2016 Chief Scientific Officer, Senior VP-R&D

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/07/2020 Carlos Alban
Vice Chairman
23,000   Disposition at $100 per share. 2,300,000
07/07/2020 Carlos Alban
Vice Chairman
30,325   Disposition at $100 per share. 3,032,500
05/12/2020 Jeffrey Ryan Stewart
SVP, US Commercial Operations
23,024   Disposition at $90 per share. 2,072,160
05/11/2020 Carrie Strom
SVP & Pres Global Allerg Aesth
23,196   Award at $0 per share. 0
05/08/2020 Thomas C. Freyman
Director
2,333   Award at $0 per share. 0
05/08/2020 Thomas C. Freyman
Director
2,583   Award at $0 per share. 0
05/08/2020 Roxanne Schuh Austin
Director
2,333   Award at $0 per share. 0
05/08/2020 Carrie Strom
SVP & Pres Global Allerg Aesth
37,903   Award at $0 per share. 0
05/08/2020 Carrie Strom
SVP & Pres Global Allerg Aesth
2,439   Award at $0 per share. 0
05/08/2020 Glenn Fletcher Tilton
Director
2,333   Award at $0 per share. 0
05/08/2020 Edward J. Rapp
Director
2,333   Award at $0 per share. 0
05/08/2020 Robert J. Alpern
Director
2,333   Award at $0 per share. 0
05/08/2020 Edward Michael Liddy
Director
2,333   Award at $0 per share. 0
05/08/2020 Frederick H. Waddell
Director
2,333   Award at $0 per share. 0
05/08/2020 William H. L. Burnside
Director
2,333   Award at $0 per share. 0
05/08/2020 Brian L. Durkin
VP, Controller
60   Award at $0 per share. 0
05/08/2020 Brett J. Hart
Director
2,333   Award at $0 per share. 0
05/08/2020 Melody B. Meyer
Director
2,333   Award at $0 per share. 0
05/08/2020 Rebecca Brown Roberts
Director
2,333   Award at $0 per share. 0
05/05/2020 Timothy J. Richmond
EVP, Chief HR Officer
19,445   Disposition at $85 per share. 1,652,825
04/28/2020 Richard A. Gonzalez
Chairman of the Board and CEO; Director
5,450   Gift at $0 per share. 0
04/28/2020 Richard A. Gonzalez
Chairman of the Board and CEO; Director
5,450   Gift at $0 per share. 0
04/28/2020 Richard A. Gonzalez
Chairman of the Board and CEO; Director
10,900   Gift at $0 per share. 0
04/28/2020 Richard A. Gonzalez
Chairman of the Board and CEO; Director
21,800   Gift at $0 per share. 0
04/06/2020 Henry O. Gosebruch
EVP, Chief Strategy Officer
18,500   Gift at $0 per share. 0
04/06/2020 Henry O. Gosebruch
EVP, Chief Strategy Officer
18,500   Gift at $0 per share. 0
04/02/2020 Laura J. Schumacher
Vice Chairman
410   Gift at $0 per share. 0
03/30/2020 Brian L. Durkin
VP, Controller
750   Acquisition at $69 per share. 51,750
03/25/2020 Richard A. Gonzalez
Chairman of the Board and CEO; Director
56,950   Gift at $0 per share. 0
/news/latest/company/us/abbv

MarketWatch News on ABBV

  1. Philip Morris and American Tower Boost Their Dividends

    8:30 a.m. Sept. 12, 2020

    - Lawrence C. Strauss

  2. U.S. Drug Stocks Are Cheap Relative to the S&P 500

    10:20 a.m. Sept. 11, 2020

    - Andrew Bary

  3. Investors Are Betting Big on a Covid-19 Vaccine. Is That Safe?

    7:44 a.m. Aug. 31, 2020

    - Josh Nathan-Kazis

  4. 5 New Stocks That Are Hedge Funds’ Favorites

    3:44 p.m. Aug. 21, 2020

    - Carleton English

  5. Don’t Just Focus on Pfizer’s Covid Vaccine, Analyst Says

    11:11 a.m. Aug. 20, 2020

    - Shaina Mishkin

  6. FDA Rejects Potential Gilead Blockbusters, Scrambling Drug Stocks

    10:42 a.m. Aug. 19, 2020

    - Josh Nathan-Kazis

  7. Buy Merck for Its Unappreciated Pipeline, Says Goldman

    10:47 a.m. Aug. 3, 2020

    - Bill Alpert

  8. AbbVie Beats Earnings Expectations but Stock Falls Anyway

    10:26 a.m. July 31, 2020

    - Josh Nathan-Kazis

  9. Loading more headlines...
/news/nonmarketwatch/company/us/abbv

Other News on ABBV

  1. 50 Billionaire Holdings, 27 Pay Dividends, 2 To Buy In September

    1:54 p.m. Sept. 18, 2020

    - Seeking Alpha

  2. Why Pfizer Is Seriously Mispriced

    11:13 a.m. Sept. 18, 2020

    - GuruFocus.com

  3. AbbVie - Still A 20% Undervalued, High-Yielding Buy

    5:35 a.m. Sept. 18, 2020

    - Seeking Alpha

  4. Interest Rates And Their Impact On Stock Values

    5:55 p.m. Sept. 17, 2020

    - Seeking Alpha

  5. AbbVie: High Yield Dividend Anxiety

    4:04 p.m. Sept. 17, 2020

    - Seeking Alpha

  6. Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

    11:45 a.m. Sept. 17, 2020

    - Zacks.com

  7. 6 Dividend Stocks To Buy For Stable Yield And Growth Potential

    10:51 a.m. Sept. 17, 2020

    - InvestorPlace.com

  8. Income Investors: Boost Your Income Using Call Options

    9:00 a.m. Sept. 16, 2020

    - Seeking Alpha

  9. Great Yield and Packed Pipeline Signal a Buy for AbbVie

    1:24 p.m. Sept. 15, 2020

    - InvestorPlace.com

  10. AbbVie: The Time Is Now

    7:34 a.m. Sept. 15, 2020

    - Seeking Alpha

  11. Dividend Aristocrats See 6 Star September Selections

    1:00 a.m. Sept. 15, 2020

    - Seeking Alpha

  12. AbbVie (ABBV) Gains But Lags Market: What You Should Know

    5:45 p.m. Sept. 14, 2020

    - Zacks.com

  13. Loading more headlines...

At a Glance

AbbVie, Inc.

1 North Waukegan Road

North Chicago, Illinois 60064-6400

Phone

1 8479327900

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$33.27B

Net Income

$7.84B

2019 Sales Growth

1.6%

Employees

30,000

/news/pressrelease/company/us/abbv

Press Releases on ABBV

  1. 2 Pharmaceutical Marijuana Stocks Showing Growth in 2020

    1:47 p.m. Sept. 17, 2020

    - Marijuana Stocks

  2. Loading more headlines...
Link to MarketWatch's Slice.